aap: 30% Nine-Month Sales Growth to EUR 24.2 million

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

aap Implantate AG, a medical technology company listed on the
Frankfurt Stock Exchange in the Prime Standard segment and active in
medical biomaterials, fracture healing and joint replacement, boosted
- according to preliminary figures - sales revenues by 36% to EUR 8,0
million (previous year: EUR 5.9 million) in the third quarter of the
fiscal year 2008. Sales growth in the first nine months was 30% to
EUR 24.2 million (previous year: EUR 18.6 million).

Sales growth was achieved by the above-average development of the
trauma & orthopaedics segment of aap throughout the first nine months
of 2008 (+57% to EUR 9.4 million) and the successful development of
the aap bio implants group in the third quarter, where revenues
exceeded the third quarter revenues of 2007 by 46%.

+-------------------------------------------------------------------+
| In EUR million | Q1 - Q3 2008 | Q1 - Q3 2007 | Change |
|----------------------------+--------------+--------------+--------|
| Sales revenues | 24.2 | 18.6 | +30% |
|----------------------------+--------------+--------------+--------|
| -thereof Trauma & | 9.4 | 6.0 | +57% |
| Orthopaedics | | | |
|----------------------------+--------------+--------------+--------|
| - thereof aap bio implants | 14.8 | 12.6 | +17% |
| group | | | |
+-------------------------------------------------------------------+

For 2008 aap anticipates an organic sales growth of more than 20%,
with above-average impact on the company's operating result and net
income. The publication of the full report on aap Implantate AG's
third quarter of 2008 is scheduled for November 7, 2008.

____
aap is a medical technology company that develops, manufactures and
markets biomaterials and implants for trauma and orthopaedics. Its
product portfolio includes bone cements, bone graft substitutes,
antibiotic carriers, and implants for fracture healing and joint
replacement. In addition to its Berlin headquarters the company has
locations in Dieburg and Obernburg near Frankfurt am Main, Düsseldorf
as well as at Nijmegen in the Netherlands. aap Implantate AG has been
listed in the Prime Standard segment at the Frankfurt stock exchange
since May 16, 2003.

Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Head of Corporate
Communications, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de

For further information about aap bio implants, visit
www.aap-bioimplants.com

--- End of Message ---

aap Implantate AG
Lorenzweg 5 Berlin Germany

WKN: 506660; ISIN:
DE0005066609; Index: CDAX, Prime All Share, TECH All Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart;
Copyright © Hugin AS 2008. All rights reserved.